Paclitaxel (175 mg/m2) and Carboplatin AUC5 (every 3 weeks) was the most used combination whether as neoadjuvant (84.8% of respondents), adjuvant after PDS (84.8–78.8% of respondents) or after NACT and IDS (78.8–69.7% of respondents), regardless of tumour and/or germline BRCA1/2 mutations. Here, BRCA1 is linked to neoplasm.